Therapeutic reprogramming of DCs—through nanoparticle-based EP2/EP4 blockade, FGL2 inhibition, STING activation, or next-generation DC vaccines—offers a strategy to convert the ovarian TME from an immunologically “cold” environment into a type I IFN-rich, DC-driven immunogenic niche capable of sustaining durable T-cell-mediated tumor control. Here, STING1 is linked to neoplasm.